Dr Eliot Brinton, Utah Lipid Center, Salt Lake City, USA discusses the unmet need for new treatments for children with homozygous familial hypercholesterolaemia (HoFH), and results of recent studies of evinacumab in children with HoFH aged 5-11 years and in those aged 12-17 years.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
